beta(3)-Adrenoceptor agonists: potential, pitfalls and progress.
about
A review of the receptor-binding properties of p-synephrine as related to its pharmacological effects'Browning' the cardiac and peri-vascular adipose tissues to modulate cardiovascular riskHuman BAT possesses molecular signatures that resemble beige/brite cellsNGF gene expression and secretion in white adipose tissue: regulation in 3T3-L1 adipocytes by hormones and inflammatory cytokinesClassification of Therapeutic and Experimental Drugs for Brown Adipose Tissue Activation: Potential Treatment Strategies for Diabetes and ObesityInsulin-sensitizing therapy attenuates type 2 diabetes-mediated mammary tumor progression.Role of Ucp1 enhancer methylation and chromatin remodelling in the control of Ucp1 expression in murine adipose tissueBeta 3-adrenoreceptor regulation of nitric oxide in the cardiovascular system.Adrenergic pathway activation enhances brown adipose tissue metabolism: a [¹⁸F]FDG PET/CT study in mice.Physiological functions and pharmacological and toxicological effects of p-octopamine.Effect of acute administration of an herbal preparation on blood pressure and heart rate in humans.Do low-affinity states of beta-adrenoceptors have roles in physiology and medicine?p-Synephrine suppresses glucose production but not lipid accumulation in H4IIE liver cells.Effects of p-synephrine alone and in combination with selected bioflavonoids on resting metabolism, blood pressure, heart rate and self-reported mood changes.Insulin sensitisation in the treatment of Type 2 diabetes.Peroxisome proliferator-activated receptor α (PPARα) induces PPARγ coactivator 1α (PGC-1α) gene expression and contributes to thermogenic activation of brown fat: involvement of PRDM16.Adipose tissue plasticity from WAT to BAT and in between.Microarray based gene expression analysis of murine brown and subcutaneous adipose tissue: significance with humanCan Brown Fat Win the Battle Against White Fat?Anti-obesity and metabolic efficacy of the β3-adrenergic agonist, CL316243, in mice at thermoneutrality compared to 22°CCardioprotective effect of beta-3 adrenergic receptor agonism: role of neuronal nitric oxide synthaseChallenges in β(3)-Adrenoceptor Agonist Drug DevelopmentCitrus aurantium and synephrine alkaloids in the treatment of overweight and obesity: an update.Beta3-adrenoreceptor stimulation ameliorates myocardial ischemia-reperfusion injury via endothelial nitric oxide synthase and neuronal nitric oxide synthase activation.AHNAK deficiency promotes browning and lipolysis in mice via increased responsiveness to β-adrenergic signallingThermogenic and metabolic antiobesity drugs: rationale and opportunities.ROS and Sympathetically Mediated Mitochondria Activation in Brown Adipose Tissue Contribute to Methamphetamine-Induced Hyperthermia.Thematic review series: adipocyte biology. Sympathetic and sensory innervation of white adipose tissue.Exercise training initiated after the onset of diabetes preserves myocardial function: effects on expression of beta-adrenoceptorsMultiple GPCR conformations and signalling pathways: implications for antagonist affinity estimates.Endogenous and Synthetic ABHD5 Ligands Regulate ABHD5-Perilipin Interactions and Lipolysis in Fat and Muscle.miR-30 promotes thermogenesis and the development of beige fat by targeting RIP140Transcriptional control of brown adipocyte development and physiological function--of mice and men.Effect of a C/EBP gene replacement on mitochondrial biogenesis in fat cells.Emerging drugs for obesity therapy.What we talk about when we talk about fat.Recent advance in brown adipose physiology and its therapeutic potential.Voluntary weight loss: systematic review of early phase body composition changes.The safety of Citrus aurantium (bitter orange) and its primary protoalkaloid p-synephrine.Cardio-selective beta-blocker: pharmacological evidence and their influence on exercise capacity.
P2860
Q26825630-953A52BE-1578-40A2-8511-4FCD867CD845Q28066261-E6816134-1151-4D65-BDAD-0A626A4905D0Q28485234-2B161001-497A-4DE3-8892-9B45C28A88B6Q28594619-A69F4DD9-3802-414A-B66A-290EBFD9B113Q33659194-B3A5263B-9571-4998-95F1-A40EEC54FC03Q33688576-C65A949D-2E95-417E-8E12-1B4BADA5E4AEQ33814183-91372822-D9C3-4160-9F66-2510648C84D0Q33838174-B69EFABD-3F4B-483F-AB50-633FBE08D5FDQ34375039-963E0ED3-F286-4F3E-A509-A7AC59398BCCQ34411379-FD94DF82-5087-49F5-BCB2-E6340D9492DAQ34648247-BFFC6E8B-FE52-4670-AA13-830AC26CACABQ34650019-0310C001-1EC5-4668-91F9-5AAC3B18C4E6Q34802533-15E884BE-D17B-474D-8E9C-2B4E229D6209Q34893795-D240FF5A-C6B4-4E53-9021-7722EF6E3626Q35073317-4D1A9960-286D-4D25-B30B-004374F10112Q35604665-96559124-6A4C-42E1-B466-21FCF18748B2Q35619414-A13086B9-4F59-4F08-AC6C-E5FC6C9ADAAEQ35641712-4581B3F5-FED2-4A96-85F4-333E7AC64832Q35782950-B9912373-EA47-4D3B-A4FF-A43A8D2BC714Q35788384-6608D4A7-451A-4C79-BB6A-66383AD46DA8Q36006132-90C88136-C207-4EB5-9CE4-721FBEB40920Q36327996-55E96950-D491-4470-9037-7774678388ACQ36377254-1525E290-953C-4573-98A8-13EB437A9068Q36652837-7801C68A-EB73-4611-B2DB-D5DC58931F17Q36700040-652DE356-63AA-4632-8666-A61FF5C4C9D5Q36772888-14B24697-19B3-489B-9EC7-CCABE1A73FFAQ36785599-E2C93E06-F242-4FAB-AD42-5E4FB4B399A6Q36802207-159B012F-39B1-447A-8D79-79AEC52332D9Q36877516-235C3630-7FA9-4867-8C14-003A76005B17Q36880896-1A4A91EE-6A85-45BA-BDCF-E94FFE551AEEQ36886505-0CD8C0B1-B120-49FC-A56C-19391289ECB6Q36926334-275AEFFB-2756-4158-84E9-DA8D7577E5C4Q37429465-21BAD772-1817-4926-915E-62DB466CFEF5Q37480418-9610ADEA-7B0F-4B1B-94C8-E160C2790D98Q37494328-6604FFD2-808B-4ECE-BDA2-A1111D24C274Q37601812-BB12F6B5-ABF4-4984-B1CA-4937D329A03CQ37621009-9C6CBD76-1B05-4C46-9004-947BAC10148AQ37762845-8DDC4123-9E44-455B-A493-FC0638CDF378Q37863654-12A3D375-7D7A-42C9-AFEE-FA7E25D6B53BQ37978886-3B94697E-F785-4327-BB0B-9E21F8288BE6
P2860
beta(3)-Adrenoceptor agonists: potential, pitfalls and progress.
description
2002 nî lūn-bûn
@nan
2002 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
name
beta(3)-Adrenoceptor agonists: potential, pitfalls and progress.
@ast
beta(3)-Adrenoceptor agonists: potential, pitfalls and progress.
@en
beta(3)-Adrenoceptor agonists: potential, pitfalls and progress.
@nl
type
label
beta(3)-Adrenoceptor agonists: potential, pitfalls and progress.
@ast
beta(3)-Adrenoceptor agonists: potential, pitfalls and progress.
@en
beta(3)-Adrenoceptor agonists: potential, pitfalls and progress.
@nl
prefLabel
beta(3)-Adrenoceptor agonists: potential, pitfalls and progress.
@ast
beta(3)-Adrenoceptor agonists: potential, pitfalls and progress.
@en
beta(3)-Adrenoceptor agonists: potential, pitfalls and progress.
@nl
P1476
beta(3)-Adrenoceptor agonists: potential, pitfalls and progress.
@en
P2093
Jonathan R S Arch
P304
P356
10.1016/S0014-2999(02)01421-8
P407
P577
2002-04-01T00:00:00Z